Hypoxia Imaging as a Radiomics Signature in Tumors Using Novel ¹⁹F-Eu-Based Contrast Agents for Magnetic Resonance...

Area of Science:

• Biomedical Imaging
• Molecular Biology
• Pathophysiology

Background:

• Hypoxia (low oxygen tension) significantly impacts various diseases, including cancer, inflammation, and cardiovascular conditions.
• Current methods lack the ability to accurately and instantaneously monitor in vivo hypoxia and correlate it with molecular signatures.
• Novel hypoxia-responsive contrast agents for magnetic resonance imaging (MRI) offer potential for real-time monitoring.

Purpose of the Study:

• To assess a novel ¹⁹F and Eu^II-based MRI contrast agent for studying hypoxia in osteosarcoma.
• To demonstrate the utility of integrating direct hypoxia imaging with spatial transcriptomic profiling.
• To establish a framework for real-time in vivo hypoxia detection and analysis.

Main Methods:

• Development and characterization of a novel hypoxia-responsive MRI contrast agent (¹⁹F and Eu^II).
• Utilized convection-enhanced delivery (CED) for MRI contrast agent distribution in osteosarcoma models.
• Integrated direct hypoxia-detecting imaging with spatial biology techniques for transcriptomic profiling.

Main Results:

• Convection-enhanced delivery (CED) proved to be a reliable method for distributing MRI contrast agents within tumors.
• The integration of hypoxia imaging and spatial biology enabled real-time in vivo biological insights.
• Identified biomarkers relevant to disease development and therapeutic response.

Conclusions:

• The novel MRI probe and integrated imaging approach facilitate direct in vivo hypoxia detection and monitoring.
• This framework provides a powerful tool for understanding hypoxia-mediated biology in various pathological conditions.
• The study lays the groundwork for translational applications in patient care and management of hypoxia-related diseases.